EA201792388A1 - Анти-ap2 антитела и антигенсвязывающие фрагменты для лечения метаболических заболеваний - Google Patents

Анти-ap2 антитела и антигенсвязывающие фрагменты для лечения метаболических заболеваний

Info

Publication number
EA201792388A1
EA201792388A1 EA201792388A EA201792388A EA201792388A1 EA 201792388 A1 EA201792388 A1 EA 201792388A1 EA 201792388 A EA201792388 A EA 201792388A EA 201792388 A EA201792388 A EA 201792388A EA 201792388 A1 EA201792388 A1 EA 201792388A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
antigen
reducing
diseases
treatment
Prior art date
Application number
EA201792388A
Other languages
English (en)
Inventor
Гёкхан С. Хотамислигил
Мехмет Ф. Бурак
Фейза Энгин
Скотт Б. Вайденмайер
Элизабет Хелен Робертс
Адриан Ричард Мур
Карл Брендан Дойл
Ральф Адамс
Карин Жаннин Мадлен Эрве
Шона Мари Уэлс
Керри Луиза Тайсон
Original Assignee
Президент Энд Феллоуз Оф Гарвард Колледж
Юсб Биофарма Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Президент Энд Феллоуз Оф Гарвард Колледж, Юсб Биофарма Спрл filed Critical Президент Энд Феллоуз Оф Гарвард Колледж
Publication of EA201792388A1 publication Critical patent/EA201792388A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)

Abstract

Данное изобретение относится к области усовершенствованных анти-aP2 антител и антигенсвязывающих фрагментов, а также их композиций, нацеленных на липидный шаперон aP2/FABP4 (также называемый "aP2"), которые предназначены для использования в лечении таких заболеваний, как диабет, ожирение, сердечно-сосудистое заболевание, жировая инфильтрация печени и/или рак, в числе прочих. Один аспект относится к усовершенствованному способу лечения опосредованных aP2 заболеваний, в котором мишенью является сывороточный aP2 и биологическая активность aP2 нейтрализуется или модулируется с помощью низкоаффинных моноклональных антител к aP2, результатом чего является снижение уровней глюкозы в крови натощак, улучшение системного метаболизма глюкозы, увеличение системной чувствительности к инсулину, снижение жировой массы, уменьшение стеатоза печени, облегчение сердечно-сосудистого заболевания и/или снижение риска развития сердечно-сосудистого заболевания.
EA201792388A 2015-04-30 2016-04-29 Анти-ap2 антитела и антигенсвязывающие фрагменты для лечения метаболических заболеваний EA201792388A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562155217P 2015-04-30 2015-04-30
US201562232148P 2015-09-24 2015-09-24
US201562268257P 2015-12-16 2015-12-16
PCT/US2016/030303 WO2016176656A2 (en) 2015-04-30 2016-04-29 Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders

Publications (1)

Publication Number Publication Date
EA201792388A1 true EA201792388A1 (ru) 2018-06-29

Family

ID=56134548

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792388A EA201792388A1 (ru) 2015-04-30 2016-04-29 Анти-ap2 антитела и антигенсвязывающие фрагменты для лечения метаболических заболеваний

Country Status (17)

Country Link
US (3) US10160798B2 (ru)
EP (1) EP3288584A2 (ru)
JP (1) JP2018515082A (ru)
KR (1) KR20170138570A (ru)
CN (1) CN107667116A (ru)
AU (1) AU2016254215A1 (ru)
BR (1) BR112017023158A2 (ru)
CA (1) CA2982427A1 (ru)
CL (1) CL2017002737A1 (ru)
CO (1) CO2017012385A2 (ru)
EA (1) EA201792388A1 (ru)
IL (1) IL255314A0 (ru)
MX (1) MX2017013807A (ru)
SG (1) SG11201708323SA (ru)
TW (1) TW201702271A (ru)
UY (1) UY36663A (ru)
WO (1) WO2016176656A2 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201702271A (zh) * 2015-04-30 2017-01-16 哈佛大學校長及研究員協會 治療代謝病症之抗－ａｐ２抗體及抗原結合劑
CA3066733A1 (en) * 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
EP3755322A4 (en) * 2018-02-19 2021-12-29 The Brigham & Women's Hospital, Inc. Targeting lipid metabolism and free fatty acid (ffa) oxidation to treat diseases mediated by resident memory t cells (trm)
WO2021226600A2 (en) * 2020-05-08 2021-11-11 President And Fellows Of Harvard College Treatment of metabolic disorders through the targeting of a novel circulating hormone complex
WO2023164727A1 (en) * 2022-02-28 2023-08-31 University Of Iowa Research Foundation A-fabp antibodies for diagnosis and treatment of obesity-associated diseases
CN118047862A (zh) * 2022-11-17 2024-05-17 港大科桥有限公司 一种a-fabp中和单克隆抗体及其制备方法和用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (ru) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
WO1986003488A1 (en) 1984-12-04 1986-06-19 Sandoz Ag Indene analogs of mevalonolactone and derivatives thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
WO1987002662A2 (en) 1985-10-25 1987-05-07 Sandoz Ag Heterocyclic analogs of mevalonolactone and derivatives thereof, processes for their production and their use as pharmaceuticals
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
SE503210C2 (sv) 1987-05-22 1996-04-22 Squibb & Sons Inc Fosforhaltiga HMG- CoA- Reduktasinhibitoret, nya intermediat och sätt
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69130741T2 (de) 1990-05-16 1999-07-29 Dana Farber Cancer Inst Inc Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4-rezeptorbindung
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
WO1994016693A1 (en) 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5889167A (en) 1996-05-22 1999-03-30 Merck & Co., Inc. Synthetic glucagon binding proteins
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
CA2344300A1 (en) 1998-09-17 2000-03-23 Jeffrey A. Robl Method for treating atherosclerosis employing an ap2 inhibitor and combination
DE60041246D1 (de) * 1999-02-12 2009-02-12 Harvard College Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US7390824B1 (en) 1999-09-07 2008-06-24 Bristol-Myers Squibb Company Method for treating diabetes employing an aP2 inhibitor and combination
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2002098917A2 (en) 2001-02-12 2002-12-12 Curagen Corporation Human proteins and nucleic acids encoding same
US6919323B2 (en) 2001-07-13 2005-07-19 Bristol-Myers Squibb Company Pyridazinone inhibitors of fatty acid binding protein and method
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
AU2002348276A1 (en) * 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
ATE468128T1 (de) 2005-07-21 2010-06-15 Biovendor Lab Medicine Inc Verfahren zur bestimmung der konzentration der adipozytaren form des fatty acid bindung protein (a-fabp, fabp4, ap2)
SG2014010029A (en) 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
WO2008144753A2 (en) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
KR101161378B1 (ko) 2008-09-09 2012-07-02 엘지전자 주식회사 백색 반사층을 구비한 박막형 태양전지 모듈 및 그 제조방법
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
ES2651503T3 (es) 2008-11-20 2018-01-26 Mesoblast, Inc. Método para tratar o prevenir una disfunción pancreática
PL2403605T3 (pl) * 2009-03-05 2016-01-29 Harvard College Kompozycje zawierające przeciwciało specyficzne względem aP2 albo jego fragment do zastosowania w leczeniu cukrzycy, nietolerancji glukozy lub insulinooporności wywołanej otyłością
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
US9062104B2 (en) * 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
CN103665139A (zh) * 2013-11-29 2014-03-26 中国药科大学 一种脂肪细胞型脂肪酸结合蛋白及其单克隆抗体的制备和应用
WO2016044337A1 (en) 2014-09-16 2016-03-24 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof
TW201702271A (zh) * 2015-04-30 2017-01-16 哈佛大學校長及研究員協會 治療代謝病症之抗－ａｐ２抗體及抗原結合劑

Also Published As

Publication number Publication date
AU2016254215A1 (en) 2017-10-26
JP2018515082A (ja) 2018-06-14
WO2016176656A3 (en) 2016-12-08
US20190161536A1 (en) 2019-05-30
TW201702271A (zh) 2017-01-16
CA2982427A1 (en) 2016-11-03
EP3288584A2 (en) 2018-03-07
WO2016176656A2 (en) 2016-11-03
CO2017012385A2 (es) 2018-04-30
BR112017023158A2 (pt) 2018-07-24
US20160319003A1 (en) 2016-11-03
KR20170138570A (ko) 2017-12-15
US20220089705A1 (en) 2022-03-24
US11014979B2 (en) 2021-05-25
US10160798B2 (en) 2018-12-25
MX2017013807A (es) 2018-03-15
UY36663A (es) 2016-07-29
IL255314A0 (en) 2017-12-31
CN107667116A (zh) 2018-02-06
SG11201708323SA (en) 2017-11-29
CL2017002737A1 (es) 2018-05-25

Similar Documents

Publication Publication Date Title
EA201792388A1 (ru) Анти-ap2 антитела и антигенсвязывающие фрагменты для лечения метаболических заболеваний
Wang et al. Enhancement of endothelial permeability by free fatty acid through lysosomal cathepsin B-mediated Nlrp3 inflammasome activation
West et al. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands
EA201201067A1 (ru) Способ получения связывающей молекулы, специфичной к белку, ассоциированному с расстройством, или антитела, или его связывающего фрагмента, или по меньшей мере одной цепи иммуноглобулина, связывающих вышеуказанный белок (варианты), связывающая молекула, антитело, цепь иммуноглобулина или их связывающий фрагмент (варианты), полинуклеотид, вектор и клетка-хозяина, их включающая композиция
Gao et al. Effects and molecular mechanism of GST-irisin on lipolysis and autocrine function in 3T3-L1 adipocytes
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
BR112017005110A2 (pt) anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
Chen et al. Knockout of neutrophil elastase protects against western diet induced nonalcoholic steatohepatitis in mice by regulating hepatic ceramides metabolism
Jäger et al. Metabolomic analysis of resveratrol-induced effects in the human breast cancer cell lines MCF-7 and MDA-MB-231
Li et al. H2S regulates endothelial nitric oxide synthase protein stability by promoting microRNA-455-3p expression
Simmons et al. Heterogeneity of endothelial cell phenotype within and amongst conduit vessels of the swine vasculature
EA202190477A1 (ru) Ацилированные миметики кальцитонина
Yu et al. miR-628 promotes burn-induced skeletal muscle atrophy via targeting IRS1
D’Souza et al. Divergent effects of cold water immersion versus active recovery on skeletal muscle fiber type and angiogenesis in young men
Zimmermann-Geller et al. Influence of extracellular RNAs, released by rheumatoid arthritis synovial fibroblasts, on their adhesive and invasive properties
EA202193296A1 (ru) Конструкции для rnai, предназначенные для подавления экспрессии scap, и способы их применения
Tranchita et al. The beneficial role of physical exercise on anthracyclines induced cardiotoxicity in breast cancer patients
Okamoto et al. Silencing of int6 gene restores function of the ischaemic hindlimb in a rat model of peripheral arterial disease
Heiat et al. Changes in mitochondrial biogenesis and fatty liver indicators in rat following continuous and high intensity interval training.
Szpak et al. αMβ2 is antiatherogenic in female but not male mice
Wesołowski et al. The influence of winter swimming on oxidative stress indicators in the blood of healthy males
Huang et al. Niacin reverses migratory macrophage foam cell arrest mediated by oxLDL in vitro
Taguchi et al. Remnant lipoprotein-cholesterol is a predictive biomarker for large artery atherosclerosis in apparently healthy women: usefulness as a parameter for annual health examinations
Werner et al. Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue
Meng et al. A microRNA circuitry links macrophage polarization to metabolic homeostasis